市場調査レポート
商品コード
1666225

治療用ワクチンの市場規模と予測(2021年~2031年)、世界・地域シェア、動向、成長機会分析:製品別、技術別、エンドユーザー別、地域別

Therapeutic Vaccines Market Size and Forecast 2021 - 2031, Global and Regional Share, Trend, and Growth Opportunity Analysis Report Coverage: By Product, Technology, End User, and Geography


出版日
ページ情報
英文 207 Pages
納期
即納可能 即納可能とは
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
治療用ワクチンの市場規模と予測(2021年~2031年)、世界・地域シェア、動向、成長機会分析:製品別、技術別、エンドユーザー別、地域別
出版日: 2025年02月07日
発行: The Insight Partners
ページ情報: 英文 207 Pages
納期: 即納可能 即納可能とは
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

治療用ワクチンの市場規模は、2024年の12億4,000万米ドルから、2031年までには29億3,000万米ドルに成長すると予測され、2024年から2031年のCAGRは13.0%と予測されています。慢性疾患の有病率の上昇、ワクチン開発への投資や資金調達の増加は、治療用ワクチン市場規模の拡大に寄与する注目すべき要因です。しかし、規制上の課題が治療用ワクチン市場の成長を妨げています。

パンデミックを引き起こす可能性のある新興病原体に対するワクチン開発は、従来の技術では実現不可能です。そのため、パンデミックの脅威に迅速に対応し、新興変異体への対策に効果的に適応できるプラットフォームを開発することが重要です。mRNAワクチン、免疫材料ベースのワクチン技術、ナノドラッグデリバリーシステム、ウイルスベクターベースのワクチンなどの革新的なワクチンプラットフォームは、治療用ワクチンの開発に革命をもたらしています。さらに、より効率的でカスタマイズ可能なワクチン技術へのシフトは、がん、自己免疫疾患、感染症を含む複数の疾患を標的とするワクチンの開発を可能にしています。mRNAワクチン技術COVID-19の成功は、がんや慢性感染症を含む感染症以外の治療用途へのmRNA技術の可能性を示しています。これらのプラットフォームは、より迅速で、より柔軟で、よりスケーラブルなワクチン製造を可能にし、新しい治療用ワクチンの開発を加速します。

研究開発者たちは、将来的な応用に向け、新たなプラットフォームを開発しています。例えば、ハーバード大学Wyss研究所の研究チームは、OMNIVAXとして知られる先駆的なワクチンプラットフォームを開発しています。この「ファーストインクラスの免疫物質ベース」ワクチン技術は、ウイルスや細菌感染に対する安全で効果的な治療・予防ワクチンの創出を目的としています。注射すると、OMNIVAXワクチンは樹状免疫細胞を引き寄せる足場を作り、特定の抗原を標的とするようプログラムします。その後、細胞は放出され、近くのリンパ節に移動し、そこで全身的かつ長期的な免疫応答を開始します。モジュール技術を用いれば、複数の抗原を一つのOMNIVAXワクチンに組み込むことができます。ワクチン技術の進歩は、今後数年間、治療用ワクチン市場に新たな動向をもたらすと思われます。

エンドユーザーに基づく洞察

エンドユーザーに基づき、治療用ワクチン市場は病院、診療所、その他に区分されます。2024年には、病院セグメントが治療用ワクチン市場で最大のシェアを占めています。治療用ワクチンは、がんやその他の慢性疾患の治療に欠かせないものとして認知されつつあり、それらは病院環境で管理されることが多いです。病院は、がんや自己免疫疾患に対する専門的な治療を実施するために必要な高度なインフラを備えています。がんを含む慢性疾患の有病率が世界的に上昇を続ける中、病院はこれらの治療に対する根強い需要を生み出しています。病院は、診断サービス、治療、治療後のモニタリングを含む包括的なケアを提供しており、これらはすべて、治療ワクチン治療を受ける患者にとって極めて重要です。さらに、病院を拠点とした研究や臨床試験の増加が、この分野の治療用ワクチン市場の拡大に寄与しています。多くの治療用ワクチンは病院内で臨床試験が行われるため、医療従事者は新しいワクチンや治療法の開発に関する最新情報を得ることができ、治療用ワクチン市場の成長に拍車をかけています。

世界保健機関(WHO)、Global Cancer Facts &Figures、米国がん協会などは、治療用ワクチン市場レポート作成時に参照した一次情報および二次情報のひとつです。

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要な洞察

第3章 調査手法

  • 2次調査
  • 1次調査
    • 仮説の策定
    • マクロ経済要因分析
    • 基礎数値の開発
    • データの三角測量
    • 国レベルのデータ

第4章 治療用ワクチンの市場情勢

  • PEST分析

第5章 治療用ワクチン市場-主要市場力学

  • 治療用ワクチン市場-主要市場力学
  • 市場促進要因
    • 慢性疾患の有病率の上昇
    • ワクチン開発への投資と資金調達の増加
  • 市場抑制要因
    • 規制上の課題
  • 市場機会
    • 製品パイプラインの拡大
  • 今後の動向
    • ワクチン技術の進歩
  • 促進要因と抑制要因の影響

第6章 治療用ワクチン市場:世界市場分析

  • 治療用ワクチン市場の収益、2021年~2031年
  • 治療用ワクチン市場の予測分析

第7章 治療用ワクチン市場分析:製品別

  • がんワクチン
  • 感染症ワクチン
  • その他

第8章 治療用ワクチン市場分析:技術別

  • 同種ワクチン
  • 自己由来ワクチン

第9章 治療用ワクチン市場分析:エンドユーザー別

  • 病院
  • 診療所
  • その他

第10章 治療用ワクチン市場:地域別分析

  • 北米
    • 米国
    • カナダ
    • メキシコ
  • 欧州
    • ドイツ
    • 英国
    • フランス
    • イタリア
    • スペイン
    • その他欧州
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • その他アジア太平洋
  • 中東・アフリカ
    • サウジアラビア
    • 南アフリカ
    • アラブ首長国連邦
    • その他中東・アフリカ
  • 中南米
    • ブラジル
    • アルゼンチン
    • その他中南米

第11章 治療用ワクチン市場-業界情勢

  • 治療用ワクチン市場における成長戦略
  • 有機的成長戦略
  • 無機的成長戦略

第12章 企業プロファイル

  • Dendreon
  • BioNTech SE
  • Serum Institute of India Pvt. Ltd
  • Merck & Co Inc
  • Amgen Inc
  • ISA Pharmaceuticals BV
  • INOVIO Pharmaceuticals Inc
  • Transgene SA
  • THERAVECTYS SA
  • CureVac SE

第13章 付録

図表

List Of Tables

  • Table 1. Therapeutic Vaccines Market Segmentation
  • Table 2. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 3. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 4. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 5. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 6. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 7. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 8. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 9. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 10. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 11. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 12. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 13. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 14. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 15. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 16. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 17. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 18. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 19. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 20. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 21. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 22. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 23. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 24. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 25. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 26. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 27. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 28. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 29. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 30. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 31. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 32. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 33. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 34. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 35. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 36. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 37. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 38. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 39. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 40. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 41. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 42. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 43. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 44. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 45. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 46. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 47. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 48. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 49. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 50. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 51. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 52. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 53. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 54. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 55. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 56. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 57. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 58. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 59. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 60. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 61. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 62. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 63. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 64. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 65. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 66. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 67. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 68. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 69. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 70. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 71. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 72. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 73. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 74. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 75. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 76. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 77. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 78. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 79. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 80. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Product
  • Table 81. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by Technology
  • Table 82. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand) - by End User
  • Table 83. Recent Organic Growth Strategies in the Therapeutic Vaccines Market
  • Table 84. Recent Inorganic Growth Strategies in the Therapeutic Vaccines Market
  • Table 85. Glossary of Terms, Therapeutic Vaccines Market

List Of Figures

  • Figure 1. Therapeutic Vaccines Market Segmentation, by Geography
  • Figure 2. PEST Analysis
  • Figure 3. Impact Analysis of Drivers and Restraints
  • Figure 4. Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • Figure 5. Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 6. Therapeutic Vaccines Market Share (%) - by Product (2024 and 2031)
  • Figure 7. Cancer Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 8. Infectious Disease Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 9. Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 10. Therapeutic Vaccines Market Share (%) - by Technology (2024 and 2031)
  • Figure 11. Allogenic Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 12. Autologous Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 13. Therapeutic Vaccines Market Share (%) - by End User (2024 and 2031)
  • Figure 14. Hospitals: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 15. Clinics: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 16. Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • Figure 17. North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 18. North America: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 19. United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 20. Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 21. Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 22. Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 23. Europe: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 24. Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 25. United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 26. France: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 27. Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 28. Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 29. Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 30. Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 31. Asia Pacific: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 32. China: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 33. Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 34. India: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 35. South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 36. Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 37. Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 38. Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 39. Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 40. Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 41. South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 42. United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 43. Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 44. South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 45. South & Central America: Therapeutic Vaccines Market Breakdown, by Key Countries, 2024 and 2031 (%)
  • Figure 46. Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 47. Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 48. Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031(US$ Thousand)
  • Figure 49. Growth Strategies in the Therapeutic Vaccines Market
目次
Product Code: TIPRE00039849

The therapeutic vaccines market size is expected to grow from US$ 1.24 billion in 2024 to US$ 2.93 billion by 2031; it is projected to register a CAGR of 13.0% during 2024-2031. The rising prevalence of chronic diseases, and increasing investments and funding for vaccine development are noteworthy factors contributing to the expansion of the therapeutic vaccines market size. However, regulatory challenges hinder the therapeutic vaccines market growth.

Developing vaccines against emerging pathogens that possess the potential to cause pandemics is not feasible using conventional technologies. As a result, it is important to develop platforms that can respond rapidly to pandemic threats and adapt effectively to measures taken to tackle emerging variants. Innovative vaccine platforms-such as mRNA vaccines, immuno-material-based vaccine technology, nano-drug delivery systems, and viral vector-based vaccines-are revolutionizing the development of therapeutic vaccines. Further, the shift toward more efficient and customizable vaccine technologies has enabled the development of vaccines that can target several diseases, including cancers, autoimmune conditions, and infectious diseases. The success of mRNA COVID-19 vaccine technology showcases promises in the potential of mRNA technology for therapeutic applications beyond infectious diseases, including cancer and chronic infections. These platforms allow for quicker, more flexible, and better scalable vaccine production, accelerating the development of new therapeutic vaccines.

Researchers are developing novel platforms for future applications. For instance, a research team at the Wyss Institute at Harvard University is developing a pioneering vaccine platform known as OMNIVAX. This "first-in-class immuno-material-based" vaccine technology aims to create safe and effective therapeutic and prophylactic vaccines against viral and bacterial infections. Upon injection, OMNIVAX vaccines establish a scaffold to attract dendritic immune cells, programming them to target a specific antigen. The cells are then released, followed by their migration to nearby lymph nodes, where they initiate a systemic and prolonged immune response. Using modular technology, multiple antigens can be incorporated into a single OMNIVAX vaccine. The advancements in vaccine technology are likely to bring new trends in the therapeutic vaccines market in the coming years.

End User-Based Insights

Based on end user, the therapeutic vaccines market is segmented into hospitals, clinics, and others. The hospitals segment held the largest therapeutic vaccines market share in 2024. Therapeutic vaccines are increasingly being recognized as a critical part of the treatment of cancer and other chronic diseases, which are frequently managed in hospital settings. Hospitals are equipped with the advanced infrastructure required to administer specialized therapies against cancer and autoimmune diseases. As the prevalence of chronic diseases, including cancer, continues to rise globally, hospitals generate a persistent demand for these treatments. Hospitals offer comprehensive care, including diagnostic services, treatment, and post-therapy monitoring, all of which are crucial for patients undergoing therapeutic vaccine treatments. Additionally, an upsurge in hospital-based research and clinical trials contributes to the expansion of the therapeutic vaccines market for this segment. Many therapeutic vaccines undergo trials within hospital environments, enabling healthcare professionals to stay updated on the development of new vaccines and treatments, fueling the therapeutic vaccines market growth.

World Health Organization's (WHO), Global Cancer Facts & Figures, and the American Cancer Society are among the primary and secondary sources referred to while preparing the therapeutic vaccines market report.

Table Of Contents

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Secondary Research
  • 3.2 Primary Research
    • 3.2.1 Hypothesis formulation:
    • 3.2.2 Macro-economic factor analysis:
    • 3.2.3 Developing base number:
    • 3.2.4 Data Triangulation:
    • 3.2.5 Country level data:

4. Therapeutic Vaccines Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. Therapeutic Vaccines Market - Key Market Dynamics

  • 5.1 Therapeutic Vaccines Market - Key Market Dynamics
  • 5.2 Market Drivers
    • 5.2.1 Rising Prevalence of Chronic Conditions
    • 5.2.2 Increasing Investments and Funding for Vaccine Development
  • 5.3 Market Restraints
    • 5.3.1 Regulatory Challenges
  • 5.4 Market Opportunities
    • 5.4.1 Extending Product Pipeline
  • 5.5 Future Trends
    • 5.5.1 Advancements in Vaccine Technology
  • 5.6 Impact of Drivers and Restraints:

6. Therapeutic Vaccines Market - Global Market Analysis

  • 6.1 Therapeutic Vaccines Market Revenue (US$ Thousand), 2021-2031
  • 6.2 Therapeutic Vaccines Market Forecast Analysis

7. Therapeutic Vaccines Market Analysis - by Product

  • 7.1 Cancer Vaccines
    • 7.1.1 Overview
    • 7.1.2 Cancer Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.2 Infectious Disease Vaccines
    • 7.2.1 Overview
    • 7.2.2 Infectious Disease Vaccines: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 7.3 Others
    • 7.3.1 Overview
    • 7.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

8. Therapeutic Vaccines Market Analysis - by Technology

  • 8.1 Allogenic Vaccine
    • 8.1.1 Overview
    • 8.1.2 Allogenic Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 8.2 Autologous Vaccine
    • 8.2.1 Overview
    • 8.2.2 Autologous Vaccine: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

9. Therapeutic Vaccines Market Analysis - by End User

  • 9.1 Hospitals
    • 9.1.1 Overview
    • 9.1.2 Hospitals: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 9.2 Clinics
    • 9.2.1 Overview
    • 9.2.2 Clinics: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
  • 9.3 Others
    • 9.3.1 Overview
    • 9.3.2 Others: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)

10. Therapeutic Vaccines Market - Geographical Analysis

  • 10.1 North America
    • 10.1.1 North America Therapeutic Vaccines Market Overview
    • 10.1.2 North America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.1.2.1 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.1.2.2 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.1.2.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.1.3 North America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.1.3.1 United States: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.1.1 United States: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.1.2 United States: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.1.3 United States: Therapeutic Vaccines Market Breakdown, by End User
      • 10.1.3.2 Canada: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.2.1 Canada: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.2.2 Canada: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.2.3 Canada: Therapeutic Vaccines Market Breakdown, by End User
      • 10.1.3.3 Mexico: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.1.3.3.1 Mexico: Therapeutic Vaccines Market Breakdown, by Product
        • 10.1.3.3.2 Mexico: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.1.3.3.3 Mexico: Therapeutic Vaccines Market Breakdown, by End User
  • 10.2 Europe
    • 10.2.1 Europe Therapeutic Vaccines Market Overview
    • 10.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.2.2.1 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.2.2.2 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.2.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.2.3 Europe: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.2.3.1 Germany: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.1.1 Germany: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.1.2 Germany: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.1.3 Germany: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.2 United Kingdom: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.2.1 United Kingdom: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.2.2 United Kingdom: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.2.3 United Kingdom: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.3 France: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.3.1 France: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.3.2 France: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.3.3 France: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.4 Italy: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.4.1 Italy: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.4.2 Italy: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.4.3 Italy: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.5 Spain: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.5.1 Spain: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.5.2 Spain: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.5.3 Spain: Therapeutic Vaccines Market Breakdown, by End User
      • 10.2.3.6 Rest of Europe: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.2.3.6.1 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Product
        • 10.2.3.6.2 Rest of Europe: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.2.3.6.3 Rest of Europe: Therapeutic Vaccines Market Breakdown, by End User
  • 10.3 Asia Pacific
    • 10.3.1 Asia Pacific Therapeutic Vaccines Market Overview
    • 10.3.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.3.2.1 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.3.2.2 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.3.2.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.3.3 Asia Pacific: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.3.3.1 China: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.1.1 China: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.1.2 China: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.1.3 China: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.2 Japan: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.2.1 Japan: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.2.2 Japan: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.2.3 Japan: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.3 India: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.3.1 India: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.3.2 India: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.3.3 India: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.4 South Korea: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.4.1 South Korea: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.4.2 South Korea: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.4.3 South Korea: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.5 Australia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.5.1 Australia: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.5.2 Australia: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.5.3 Australia: Therapeutic Vaccines Market Breakdown, by End User
      • 10.3.3.6 Rest of APAC: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.3.3.6.1 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Product
        • 10.3.3.6.2 Rest of APAC: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.3.3.6.3 Rest of APAC: Therapeutic Vaccines Market Breakdown, by End User
  • 10.4 Middle East & Africa
    • 10.4.1 Middle East & Africa Therapeutic Vaccines Market Overview
    • 10.4.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.4.2.1 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.4.2.2 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.4.2.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.4.3 Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.4.3.1 Saudi Arabia: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.1.1 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.1.2 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.1.3 Saudi Arabia: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.2 South Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.2.1 South Africa: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.2.2 South Africa: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.2.3 South Africa: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.3 United Arab Emirates: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.3.1 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.3.2 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.3.3 United Arab Emirates: Therapeutic Vaccines Market Breakdown, by End User
      • 10.4.3.4 Rest of Middle East & Africa: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.4.3.4.1 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Product
        • 10.4.3.4.2 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.4.3.4.3 Rest of Middle East & Africa: Therapeutic Vaccines Market Breakdown, by End User
  • 10.5 South & Central America
    • 10.5.1 South & Central America Therapeutic Vaccines Market Overview
    • 10.5.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
      • 10.5.2.1 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Product
      • 10.5.2.2 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Technology
      • 10.5.2.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by End User
    • 10.5.3 South & Central America: Therapeutic Vaccines Market - Revenue and Forecast Analysis - by Country
      • 10.5.3.1 Brazil: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.1.1 Brazil: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.1.2 Brazil: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.1.3 Brazil: Therapeutic Vaccines Market Breakdown, by End User
      • 10.5.3.2 Argentina: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.2.1 Argentina: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.2.2 Argentina: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.2.3 Argentina: Therapeutic Vaccines Market Breakdown, by End User
      • 10.5.3.3 Rest of South & Central America: Therapeutic Vaccines Market - Revenue and Forecast to 2031 (US$ Thousand)
        • 10.5.3.3.1 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Product
        • 10.5.3.3.2 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by Technology
        • 10.5.3.3.3 Rest of South & Central America: Therapeutic Vaccines Market Breakdown, by End User

11. Therapeutic Vaccines Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Growth Strategies in the Therapeutic Vaccines Market
  • 11.3 Organic Growth Strategies
    • 11.3.1 Overview
  • 11.4 Inorganic Growth Strategies
    • 11.4.1 Overview

12. Company Profiles

  • 12.1 Dendreon
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 BioNTech SE
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Serum Institute of India Pvt. Ltd
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Merck & Co Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Amgen Inc
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 ISA Pharmaceuticals BV
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 INOVIO Pharmaceuticals Inc
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Transgene SA
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 THERAVECTYS SA
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments
  • 12.10 CureVac SE
    • 12.10.1 Key Facts
    • 12.10.2 Business Description
    • 12.10.3 Products and Services
    • 12.10.4 Financial Overview
    • 12.10.5 SWOT Analysis
    • 12.10.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms